The metabolic syndrome: Peroxisome proliferator-activated receptor γ and its therapeutic modulation

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 6, 2003, Pages 2412-2421

  Gurnell, Mark ^a   Savage, David B ^b   Chatterjee, V Krishna K ^a   O'Rahilly, Stephen ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TROGLITAZONE;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; DYSLIPIDEMIA; GENETIC LINKAGE; GLUCOSE HOMEOSTASIS; HERITABILITY; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN ISOLATION; REVIEW;

EID: 0038645828     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030435     Document Type: Review

References (97)

1. Zimmet P, Alberti KG, Shaw J 2001 Global and societal implications of the diabetes epidemic. Nature 414:782-787
2. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE 2002 The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25:829-834
3. Saydah SH, Loria CM, Eberhardt MS, Brancati FL 2001 Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24:447-453
4. Unwin N, Shaw J, Zimmet P, Alberti KG 2002 Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708-723
5. Reaven GM 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
6. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689
7. Willson TM, Brown PJ, Sternbach DD, Hanke BR 2000 The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550
8. Issemann I, Green S, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. 1990 Nature 347:645-650
9. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ 1993 Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 31:857-907
10. Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IF 1994 Mechanistically based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 13(Suppl 2):S1-S117
11. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W 1996 Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354-366
12. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, Palmer CN 2001 The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276:44258-44265
13. Oliver Jr WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM 2001 A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311
14. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK 1993 Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem 268:26817-26820
15. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J 1997 The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779-18789
16. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812
17. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM, Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. 1997 Proc Natl Acad Sci USA 94:4318-4323
18. Nagy L, Tontonoz PA, Alvarez JG, Chen H, Evans RM 1998 Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229-240
19. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM 2000 Transcriptional regulation of adipogenesis. Genes Dev 14:1293-1307
20. Rosen ED, Spiegelman BM 2001 PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734
21. Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, Briggs M 1999 Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis. Cell Growth Differ 10:43-48
22. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM 2002 C/EBPalpha induces adipogenesis through PPAR-gamma: a unified pathway. Genes Dev 16:22-26
23. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM, PPARγ is required for placental, cardiac and adipose tissue development. 1999 Mol Cell 4:585-595
24. Kubota NT, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T, et al. 1999 PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609
25. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T 2001 The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245-41254
26. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS 1997 Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416-2422
27. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S 1997 Activators of PPARγ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153
28. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK 2000 A dominant negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem 275:5754-5759
29. Larsen TM, Toubro S, Astrup A 2003 PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 27:147-161
30. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S 2002 Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 51:718-723
31. Jensen MD 1997 Lipolysis: contribution from regional fat. Annu Rev Nutr 17:127-139
32. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S 1999 Dominant negative mutations in human PPARγ are associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
33. Agarwal AK, Garg A 2002 A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408-411
34. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T 2002 PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586-3590
35. Chatterjee VKK 2001 Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor γ resistance. Biochem Soc Trans 29:227-231
36. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S 2003 Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor PPARγ. Diabetes 52:910-917
37. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR 1998 Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339:953-959
38. Hu E, Kim JB, Sarraf P, Spiegelman BM 1996 Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 274:2100-2103
39. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VKK 1997 Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128-5132
40. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES 2000 The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80
41. Stumvoll M, Haring H 2002 The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51:2341-2347
42. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS 2002 PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16:27-32
43. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J 1998 A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
44. Day C 1999 Thiazolidinediones: a new class of antidiabetic drugs. 1999 Diabet Med 16:179-192
45. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956
46. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM 1996 The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668
47. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD 1996 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195
48. Watkins PB, Whitcomb RW 1998 Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917
49. Schoonjans K, Auwerx J 2000 Thiazolidinediones: an update. Lancet 355:1008-1010
50. Fiedorek FT, Wilson GG, Frith L, Patel J, Abou-Donia M 2000 Monotherapy with G1262570, a tyrosine-based non-thiazolidinedione PPARγ agonist, improves metabolic control in type 2 diabetes mellitus patients. Diabetes 49(Suppl 1):Abstract 157-OR
51. Mukherjee R, Davies PJA, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti Jr JR, Heyman RA 1997 Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410
52. Picard F, Auwerx J 2002 PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167-197
53. Reitman ML, Arioglu E, Gavrilova O, Taylor SI 2000 Lipoatrophy revisited. Trends Endocrinol Metab 11:410-416
54. Muoio DM, Dohm GL, Fiedorek Jr FT, Tapscott EB, Coleman RA, Dohn GL 1997 Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 46:1360-1363
55. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749
56. Hotamisligil GS, Spiegelman BM 1994 Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43:1271-1278
57. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409:307-312
58. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T 2001 The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946
59. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y 2001 Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133
60. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953
61. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchl N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y 2001 PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099
62. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE 2002 Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998-1007
63. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V 1999 Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 48:1466-1468
64. Ringel J, Engeli S, Distler A, Sharma AM 1999 Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 254:450-453
65. Meirhaeghe A, Fajas L, Helbecque N, et al. 2000 Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 24:195-199
66. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T 2000 The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212-216
67. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C 2000 The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 24:391-393
68. Beamer BA, Yen C-J, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR 1998 Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47:1806-1808
69. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M 1999 Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84:3708-3712
70. . Cole SA, Mitchell BD, Hsueh WC, Pineda P, Beamer BA, Shuldiner AR, Comuzzie AG, Blangero J, Hixson JE 2000 The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 24:522-524
71. Luan J, Browne PO, Harding AH, Halsall DJ, O'Rahilly S, Chatterjee VK, Wareham NJ 2001 Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686-689
72. Miles PD, Barak Y, He W, Evans RM, Olefsky JM 2000 Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105:287-292
73. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ 2002 Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31:379-384
74. Ginsberg HN 2000 Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458
75. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA 2001 Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134:61-71
76. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M 1998 Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 123:675-682
77. Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M, Maekawa H, Isoo N, Kimura S, Watanabe T 1999 Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Comm 254:757-763
78. Itoh H, Doi K, Tanaka T, Fukunaga Y, Hosoda K, Inoue G, Nishimura H, Yoshimasa Y, Yamori Y, Nakao K 1999 Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor γ. Clin Exp Pharmacol Physiol 26:558-560
79. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G 1998 Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47:810-814
80. Martin G, Schoonjans K, Staels B, Auwerx J 1998 PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137(Suppl):S75-S80
81. Guan H-P, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA 2002 A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122-1128
82. Oakes ND, Thalen PG, Jacinto SM, Ljung B 2001 Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158-1165
83. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H 1998 Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820
84. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y 2001 Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456
85. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM 1998 PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252
86. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK 1998 Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614-7619
87. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J 1998 Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153:17-23
88. Jiang C, Ting AT, Seed B 1998 PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
89. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK 1998 The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-86
90. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW 2001 The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47
91. Tall AR, Costet P, Wang N 2002 Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest 110:899-904
92. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B 2001 PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58
93. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM 2001 PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52
94. Yang W, Rachez C, Freedman LP 2000 Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol 20:8008-8017
95. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti Jr JR 2000 A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14:1425-1433
96. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM 1999 A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 96:6102-6106
97. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J 2001 A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-747